Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 8
Submit an article Journal homepage
715
Views
22
CrossRef citations to date
0
Altmetric
Reviews

Treatment strategies for myasthenia gravis

J Díaz-Manera Universitat Autònoma Barcelona, Hospital Santa Creu i Sant Pau, Neuromuscular Diseases Unit, Neurology Department, Av. Sant Antoni Maria Claret 167, 08025 Barcelona, Spain +34 93 556 5986; +34 93 556 5602; [email protected]
, MD,
R Rojas-García Universitat Autònoma Barcelona, Hospital Santa Creu i Sant Pau, Neuromuscular Diseases Unit, Neurology Department, Av. Sant Antoni Maria Claret 167, 08025 Barcelona, Spain +34 93 556 5986; +34 93 556 5602; [email protected]
, MD PhD &
Isabel Illa Universitat Autònoma Barcelona, Hospital Santa Creu i Sant Pau, Neuromuscular Diseases Unit, Neurology Department, Av. Sant Antoni Maria Claret 167, 08025 Barcelona, Spain +34 93 556 5986; +34 93 556 5602; [email protected]
, MD PhD
Pages 1329-1342 | Published online: 15 May 2009

Bibliography

  • Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29(4):484-505
  • Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001;357(9274):2122-8
  • Howard JF, Sanders DB. The management of patients with myasthenia gravis. In: Alburquerque, Eldefrawi AT, editors, Myasthenia gravis. London, New York: Chapman and Hall, 1983. p. 457-89
  • Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology 2000;55:16-23
  • McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-4
  • Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116(11):2843-54
  • Sahashi K, Engel AG, Lambert EH, nd Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 1980;39:160-72
  • Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-68
  • Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(10):2304-11
  • Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60(12):1978-80
  • Illa I, Diaz-Manera JA, Juarez C, et al. Seronegative myasthenia gravis and antiMuSK positive antibodies: description of Spanish series. Med Clin (Barc) 2005;125(3):100-2
  • Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann NY Acad Sci 2008;1132:71-5
  • Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci 2008;1132:76-83
  • Engel AG, Lambert EH, Santa T. Study of long term anticholinesterase therapy. Neurology 1973;23:1273-81
  • Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton Myasthenic syndrome. Semin Neurol 2003;23:191-8
  • Evoli A, Batocchi AP, Minisci C, et al. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001;11:208-16
  • Papatestas AE, Alpert LJ, Osserman KE, et al. Studies in myasthenia gravis. Effects of thymectomy. Results on 185 patients with non-thymoma and thymomathous myasthenia gravis. Am J Med 1971;50:465-74
  • Gronseth G, Barohn RJ. Practice parameter: thymectomy for autoinmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 2000;55:7-15
  • Newsom-Davis J, Cutter G, Wolfe GI, et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann NY Acad Sci 2008;1132:344-7
  • Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005;57:444-8
  • Sonett JR, Jaretzki A 3rd. Thymectomy for nonthymomatous myasthenia gravis: a critical analysis. Ann NY Acad Sci 2008;1132:315-28
  • Nieto JP, Robledo JP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thor Surg 1999;67:1568-71
  • Wright CD. Management of thymomas. Crit Rev Oncol Hematol 2007;65:109-20
  • Kesler KA, Wright CD, Loehrer PJS. Thymoma: current medical and surgical management. Semin Neurol 2004;24:63-73
  • Tindall RS. Humoral immunityin myasthenia gravis: effect of steroids and thymectomy. Neurolog 1980;30:554-57
  • Hohlfeld R, Dalakas M. Basic principles of immunotherapy for neurologic diseases. Semin Neurol 2003;23:121-31
  • Taylor AL, Watson CJE, Bradley A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005;56:23-46
  • Warmolts JR, Genkins G. Benefit from alternate day prednisone in myasthenia gravis. N Engl J Med 1972;286:17-20
  • Mount FW. Corticotropin in treatment of ocular myasthenia. Arch Neurol 1964;11:114-24
  • Howard JR JF, Duane DD, Lambert EH, Daube JR. Alternate day prednisone: preliminary report of a double-blind controlled study. Ann NY Acad Sci 1976;274:596-607
  • Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998;97:370-3
  • Zhang J, Wu H. Effectiveness of steroid treatment in juvenile myasthenia gravis. Chin J Ped 1998;36:612-4
  • Simon HE. Myasthenia gravis: effect of treatment with anterior pituitary extract. JAMA 1935;104:2065-6
  • Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-8
  • Sghirlanzoni A, Peluchetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984;34:170-4
  • Cosi V, Citterio A, Lombardi M, et al. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study. Acta Neurol Scand 1991;84:33-9
  • Evoli A, Batocchi AP, Palmisani MT, et al. Long term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992;32:37-43
  • Bu B, Yang M, Xu J, et al. A prospective study of effectiveness and safety of long-term prednisone therapy in patients with myasthenia gravis. Chin J Neurol 2000;33:28-31
  • Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld R. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005;(2)
  • Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol 2008;2008:317-27
  • Cara CJ, Pena AS, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit 2004;10:247-54
  • Ferrero S, Esposito F, Biamonti M, et al. Myasthenia gravis during pregnancy. Expert Rev Neurother 2008;8:979-88
  • Gajdos P. Myasthenia gravis clinical study group. A randomised clinical trial comparing prednisolone and azathioprine in myasthenia gravis. Results of a second interim analysis. J Neurol Neurosurg Psychiatry 1993;56:1157-63
  • Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-83
  • Delwaide PJ, Salmon J, Van Cauwenberge H. Preliminary observations of the treatment of myasthenia gravis by azathioprine. Acta Neurol Psychiatr Belg 1964;67:701-12
  • Matell G, Bergström K, Franksson C, et al. Effects of some immunosuppressive procedures in myasthenia gravis. Ann NY Acad Sci 1976;274:659-76
  • Witte AS, Cornblath DR, Parry GJ, et al. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984;15:602-5
  • Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-42
  • Kuks JBM, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord 1991;1:423-31
  • Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-53
  • Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 2004;39(2):85-128
  • Busauschina A, Schnuelle P, Van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc 2004;36:229S-33S
  • Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13(5):313-26
  • Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316(12):719-24
  • Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 1993;681:539-51
  • Goulon M, Elkharrat D, Lokiec F, Gajdos P. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis. Transplant Proc 1988;20(3 Suppl 4):211-7
  • Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997;244:542-7
  • Lavrnic D, Vujic A, Rakocevic-Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 2005;111:247-52
  • Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis: a randomized pilot study. Eur Neurol 2005;53:146-50
  • Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003;28:570-4
  • Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005;76:448-50
  • Kawaguchi N, Yoshiyama Y, Nemoto Y, et al. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004;20:1269-73
  • Ponseti JM, Azam J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisolone-dependent myasthenia gravis. Neurology 2005;64:1641-3
  • Allison C, Euqui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology 2000;47:85-118
  • Sieb JP. Myasthenia gravis: emerging new therapy options. Curr Opin Pharmacol 2005;5:303-7
  • Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann NY Acad Sci 2003;998:494-9
  • Sanders DB, Hart IK, Mantegazza R, et al. An international phase III, randomized trial of mycophenolate mofetil for myasthenia gravis. Neurology 2008;71:400-6
  • Group MS. A trial of mycophenolate mofetil with prednisone as initial imunotherapy in myasthenia gravis. Neurology 2008;71:394-9
  • Cos L, Mankodi AK, Tawil T, Thornton CA. Mycophenolate mofetil (MyM) is safe and well tolerated in myasthenia gravis (MG). Neurology;54(Suppl 3):A137
  • Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001;56:97-9
  • Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003;61:1438-40
  • De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26:31-6
  • Perez MC, Buot WL, Mercado-Danguilan C, et al. Stable remissions in myasthenia gravis. Neurology 1981;31:32-7
  • Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia gravis: ‘rebooting’ with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34
  • Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci 2008;1132:305-14
  • Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 2007;7:405-411
  • Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Trasnplant 2006;65:859-66
  • Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008;47:224-5
  • Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive Myasthenia Gravis with rituximab. Muscle Nerve 2006;33:575-80
  • Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-hodgkin lymphoma. Am J Hematol 2004;77:196-7
  • Diaz-Manera JA, Rojas-Garcia R, Gallardo E, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and morvan syndrome. Nat Clin Pract Neurol 2007;3:405-10
  • Illa I, Diaz-Manera JA, Rojas-Garcia R, et al. Sustained response to rituximab in anti-AChR and MuSK positive myasthenia gravis patients. J Neuroimmunol 2008;15(201-202):90-4
  • Gold R, Stangel M, Dalakas M. Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nat Clin Pract Neurology 2006;3:36-44
  • Dalakas M. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-75
  • Dalakas M. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharm Therap 2004;102:177-93
  • Lisak RP. Plasmaexchange in neurologic disease. Arch Neurol 1984;41:647-54
  • Lehmann HC, Hartung HP, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006;63(7):930-5
  • Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997;41:789-96
  • Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-32
  • Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837-841
  • Perez Nellar J, Dominguez AM, Llorens-Figueroa JA, et al. A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia. Rev Neurol 2001;33:413-6
  • Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003;61:1652-61
  • Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000;23:551-5
  • Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008, Issue1. Art. No.: CD002277. DOI: 10.1002/14651858.CD002277.pub3
  • Newson-Davis J, Vincent A, Wilson SG, et al. Plasmapheresis for myasthenia gravis. N Engl J Med 1978;298:456-7
  • Pinching AJ, Peters DK, Newson-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet 1976;2(8000):1373-76
  • Behan PO, Shakir RA, Simpson JA, et al. Plasma exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet 1979;2:438-40
  • Skeie GO, Apostolski S, Evoli A, et al. EFNS task force article: guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006;13:691-9
  • Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; Issue 4. Art. No:CD005224. DOI: 10.1002/14651858.CD005224.pub2
  • Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 2005;62:442-46
  • Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thor Surg 2008;86:673-84
  • Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 2002;59:1844-50
  • Kuppersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Opthamol 2005;89:1330-34
  • Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008;21:8-15
  • Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol 2008;255:510-3
  • Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis reducing the hazards of treatment. N Engl J Med 1974;290:81-4
  • Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. J Neurol 2005;252(Suppl 1):14-8
  • Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS Task Force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008;15:893-908
  • Flacke W. Treatment of myasthenia gravis. N Engl J Med1973;288:27-31

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.